Risk of seizures associated with psychotropic medications: emphasis on new drugs and new findings

Bibliography

• ANTON-STEPHENS D: Preliminary observations on the psychiatric use of chlorpromazine. I Merit. Sri. (1954) 100:543–557.
   Google Scholar
• MESSING RO, CLOSSON RG, SIMON RP: Drug-induced seizures: a 10-year experience. Neurology (1984) 34:1582–1586.
   PubMed Web of Science ®Google Scholar
• KOGEORGOS J, FONAGY P, SCOTT DF: Psychiatric symptom patterns of chronic epileptics attending a neurological clinic: a controlled investigation. Br. J. Psychiatry (1982) 140:236–243.
   PubMed Web of Science ®Google Scholar
• HAWTON K, FAGG J, MARSACK P: Association between epilepsy and attempted suicide. I Neural. Neurosurg. Psychiatry (1980) 43:168–170.
   PubMed Web of Science ®Google Scholar
• PISANI F, OTERI G, COSTA C, DI RAIMONDO G, DI PERRI R: Effects of psychotropic drugs on seizure threshold. Drug Sal (2002) 25:91–110.
   PubMed Web of Science ®Google Scholar
• ••An excellent review that discusses seizurerisk associated with psychotropic drugs. It also discusses patient- and drug-related factors as well as methodological issues in capturing absolute and relative risk of drug-induced seizures.
   Google Scholar
• ALLDREDGE BK: Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology (1999) 53:S68–S75.
   PubMed Web of Science ®Google Scholar
• DAILEY JW, NARITOKU DK: Antidepressants and seizures: clinical anecdotes overshadow neuroscience. Biochem. Pharmacol (1996) 52:1323–1329.
   PubMed Web of Science ®Google Scholar
• •Provocative summary of evidence linking psychotropes as a cause or treatment of seizures; also includes speculation on possible mechanisms.
   Google Scholar
• MILLICHAP JG: Anticonvulsant Drugs. In: Physiological pharmacology: a comprehensive treastise. Root WS, Hoffman FG (Eds), Academic Press, New York (1965):97–173.
   Google Scholar
• FROMM GH, WESSEL HB, GLASS JD, ALVIN JD, VAN HORN G: Imipramine in absence and myoclonic-astatic seizures. Neurology (1978) 28:953–957.
   PubMed Web of Science ®Google Scholar
• HARDEN CL: The comorbidity of depression and epilepsy: epidemiology, etiology, and treatment. Neurology (2002) 59:S48–S55.
   PubMed Web of Science ®Google Scholar
• LEYBERG JT, DENMARK JC: The treatment of depressive states with imipramine hydrochloride (Tofrani1). Merm Sci. (1959) 105:1123–1126.
   Web of Science ®Google Scholar
• OLSON KR, KEARNEY TE, DYER JE, BENOWITZ NL, BLANC PD: Seizures associated with poisoning and drug overdose. Am. j Emerg. Med. (1994) 12:392–395.
   PubMedGoogle Scholar
• HAUSER WA, KURLAND LT: The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia (1975) 16:1–66.
   PubMed Web of Science ®Google Scholar
• PECK AW, STERN WC, WATKINSON C:Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. j Clin. Psychiatry (1983) 44:197–201.
   PubMed Web of Science ®Google Scholar
• PRESKORN SH, FAST GA: Tricyclic antidepressant-induced seizures and plasma drug concentration. j Clin. Psychiatry (1992) 53:160–162.
   PubMed Web of Science ®Google Scholar
• SCHMID B, BIRCHER J, PREISIG R, KUPFER A: Polymorphic dextromethorphan metabolism: co-segregation of oxidative 0-demethylation with debrisoquin hydroxylation. Pharmacol Ther. (1985) 38:618–624.
   Web of Science ®Google Scholar
• JEFFERSON JW: Drug interactions - friend or foe? J Clin. Psychiatry (1998) 59(Suppl 4):37–47.
   Google Scholar
• OJEMANN LM, FRIEL PN, TREJO WJ, DUDLEY DL: Effect of doxepin on seizure frequency in depressed epileptic patients. Neurology (1983) 33:646–648.
   PubMed Web of Science ®Google Scholar
• ROSENSTEIN DL, NELSON JC, JACOBS SC: Seizures associated with antidepressants: a review. I Clin. Psychiatry (1993) 54:289–299.
   PubMed Web of Science ®Google Scholar
• WEDIN GP, ODERDA GM, KLEIN-SCHWARTZ W, GORMAN RL: Relative toxicity of cyclic antidepressants. Ann. Emerg. Med. (1986) 15:797–804.
   PubMed Web of Science ®Google Scholar
• JOBE PC, LAIRD HE: Neurotransmitter abnormalities as determinants of seizure susceptibility and intensity in the genetic models of epilepsy. Biochem. Pharmacol (1981) 30:3137–3144.
   PubMed Web of Science ®Google Scholar
• KILLAM EK, KILLAM KF Jr: Evidence forneurotransmitter abnormalities related to seizure activity in the epileptic baboon. Fed. Proc. (1984) 43:2510–2515.
   PubMedGoogle Scholar
• FROMM GH, AMORES CY, THIES W: Imipramine in epilepsy. Arch. Neural. (1972) 27:198–204.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ EJ, WILLIAMS PA, DUDEK FE: Effects of fluoxetine and TFIVIPP on spontaneous seizures in rats with pilocarpine-induced epilepsy. Epilepsia (2002) 43:1337–1345.
   PubMed Web of Science ®Google Scholar
• YAN QS, MISHRA PK, BURGER RL, BETTENDORF AF, JOBE PC, DAILEY JW: Evidence that carbamazepine and antiepilepsirine may produce a component of their anticonvulsant effects by activating serotonergic neurons in genetically epilepsy-prone rats. I Pharmacol Exp. Ther. (1992) 261:652–659.
   PubMed Web of Science ®Google Scholar
• COOPER GL: The safety of fluoxetine - an update. Br I Psychiatry Suppl. (1988) 3:77–86.
   PubMedGoogle Scholar
• BRAITBERG G, CURRY SC: Seizure after isolated fluoxetine overdose. Ann. Emerg. Med. (1995) 26:234–237.
   PubMed Web of Science ®Google Scholar
• BORYS DJ, SETZER SC, LING LJ, REISDORF JJ, DAY LC, KRENZELOK EP: Acute fluoxetine overdose: a report of 234 cases. Am. I Emerg. Med. (1992) 10:115–120.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Physicians' Desk Reference. Medical Economics Company, Inc., Montvale (1992).
   Google Scholar
• PRENDIVILLE S, GALE K: Anticonvulsant effect of fluoxetine on focally evoked limbic motor seizures in rats. Epilepsia (1993) 34:381–384.
   PubMed Web of Science ®Google Scholar
• FAVALE E, RUBINO V, MAINARDI P, LUNARDI G, ALBANO C: Anticonvulsant effect of fluoxetine in humans. Neurology (1995) 45:1926–1927.
   PubMed Web of Science ®Google Scholar
• LEANDER JD: Fluoxetine, a selective serotonin-uptake inhibitor, enhances the anticonvulsant effects of phenytoin, carbamazepine, and ameltolide (LY201116). Epilepsia (1992) 33:573–576.
   PubMed Web of Science ®Google Scholar
• VAN HARTEN J: Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin. Pharmacokinet. (1993) 24:203–220.
   PubMed Web of Science ®Google Scholar
• DUNCAN D, TAYLOR D: What is the safest antidepressant to use in epilepsy? Psychiatric Bull. (1995) 19:355–357.
   Google Scholar
• HARMANT J, VAN RIJCKEVORSEL-HARMANT K, DE BARSY T, HENDRICKX B: Fluvoxamine: an antidepressant with low (or no) epileptogenic effect. Lancet (1990) 336:386.
   PubMed Web of Science ®Google Scholar
• SEDGWICK EM, CILASUN J, EDWARDS JG: Paroxetine and the electroencephalogram. J. Clin. Psychopharmacol (1987) 1:31–34.
   Google Scholar
• HOVORKA J, HERMAN E, NEMCOVA I: Treatment of interictal depression with citalopram. Epilepsy Behav. (2000) 1:444–447.
   PubMed Web of Science ®Google Scholar
• MITCHELL PB: Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Sal (1997) 17:390–406.
   PubMed Web of Science ®Google Scholar
• BOUMAN WE PINNER G, JOHNSON H: Incidence of selective serotonin reuptake inhibitor (SSRI)-induced hyponatraemia due to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion in the elderly. Int. J. Geriatr. Psychiatry (1998) 13:12–15.
   PubMed Web of Science ®Google Scholar
• HORNE RL, FERGUSON JM, POPE HG Jr et al.: Treatment of bulimia with bupropion: a multicenter controlled trial. j OM. Psychiatry (1988) 49:262–266.
   Google Scholar
• CARSON SW: Bupropion, is it here to stay? DICP (1989) 23:704–705.
   PubMedGoogle Scholar
• DAVIDSON J: Seizures and bupropion: a review. J. OM. Psychiatry (1989) 50:256–261.
   Google Scholar
• DAVIDSON JR, CONNOR KM: Bupropion sustained release: a therapeutic overview. J. OM. Psychiatry (1998) 59\(Suppl. 4):25–31.
   Google Scholar
• DUNNER DL, ZISOOK S, BILLOW AA,BATEY SR, JOHNSTON JA, ASCHER JA: A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J. OM. Psychiatry (1998) 59:366–373.
   Google Scholar
• NO AUTHORS LISTED: Wellbutrin sustained-release tablets (bupropion hydrochloride) (package insert). Research Triangle Park, North Carolina (1996).
   Google Scholar
• HESSE LM, VENKATAKRISHNAN K, COURT MH et al: CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Dug Metab. Dispos. (2000) 28:1176–1183.
   PubMed Web of Science ®Google Scholar
• BOWDAN ND: Seizure possibly caused bytrazodone HC1. Am. J. Psychiatry (1983) 140:642.
   PubMed Web of Science ®Google Scholar
• LEFKOWITZ D, KILGO G, LEES: Seizures and trazodone therapy. Arch. Gen. Psychiatry (1985) 42:523.
   PubMed Web of Science ®Google Scholar
• HENRY JA, ALI CJ, CALD WELL R, FLANAGAN RJ: Acute trazodone poisoning: clinical signs and plasma concentrations. Psychopathology (1984) 17\(Suppl. 2):77–81.
   Google Scholar
• ROBINSON DS, ROBERTS DL, SMITH JM et al.: The safety profile of nefazodone. j Clin. Psychiatry (1996) 57\(Suppl. 2):31–38.
   Google Scholar
• OWEN JR, NEMEROFF CB: New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress. Anzio, (1998) 7\(Suppl. 1):24–32.
   Google Scholar
• NO AUTHORS LISTED: Nefazodone and liver damage. Harv. Ment. Health Lett. (2002) 19:8.
   Google Scholar
• RUDOLPH RL, DERIVAN AT: The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J. Clin. Psychopharmacol (1996) 16:S54-S59. Discussion S59–S61.
   Google Scholar
• NO AUTHORS LISTED: Effexor tablets (venlafaxine hydrochloride) (package insert). Philadelphia, PA (1997).
   Google Scholar
• SANTOS JG Jr, DO MONTE FH, RUSSI M, AGUSTINE PE, LANZIOTTI VM: Proconvulsant effects of high doses of venlafaxine in pentylenetetrazole-convulsive rats. Braz J. Med. Biol. Res. (2002) 35:469–472.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY SA: Safety of mirtazapine: a review. Int. Clin. Psychopharmacol (1995) 10\(Suppl. 4):37–45.
   Google Scholar
• STIMMEL GL, DOPHEIDE JA, STAHL SM: Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy (1997) 17:10–21.
   PubMed Web of Science ®Google Scholar
• LAMBERT MV, ROBERTSON MM: Depression in epilepsy: etiology, phenomenology, and treatment. Epi/epsia (1999) 40\(Suppl. 10):521–547.
   Google Scholar
• NO AUTHORS LISTED: Tranylcypromine (package insert). Philadelphia, PA (2001).
   Google Scholar
• NO AUTHORS LISTED: Phenelzine (package insert). Morris Plains, NJ (2001).
   Google Scholar
• AMREIN R, GUNTERT TW, DINGEMANSE J, LORSCHEID T, STABL M, SCHMID-BURGK W: Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies. Psychopharmacology (Berl) (1992) 106(Suppl.):824–831.
   Google Scholar
• NO AUTHORS LISTED: Reboxetine (package insert). Peapack, NJ (1997).
   Google Scholar
• STIMMEL GL, DOPHEIDE JA: Psychotropic drug-induced reductions in seizure threshold. CNS Drugs (1996) 5:37–50.
   Web of Science ®Google Scholar
• ITIL TM, SOLDATOS C: Epileptogenic side effects of psychotropic drugs. Practical recommendations. JAMA (1980) 244:1460–1463.
   Google Scholar
• QUITKIN E RIFKIN A, KLEIN DF: Very high dosage versus standard dosage fluphenazine in schizophrenia. A double-blind study of nonchronic treatment-refractory patients. Arch. Gen. Psychiatry (1975) 32:1276–1281.
   Google Scholar
• REMICK RA, FINE SH: Antipsychotic drugs and seizures. J. Clin. Psychiatry (1979) 40:78–80.
   PubMed Web of Science ®Google Scholar
• TRIMBLE MR: The psychoses of epilepsy and their treatment. Clin. Neuropharmacol (1985) 8:211–220.
   PubMed Web of Science ®Google Scholar
• LOGOTHETIS J: Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology (1967) 17:869–877.
   PubMed Web of Science ®Google Scholar
• •Landmark review of experience with clozapine in 7000 patients over 16 years.
   Google Scholar
• DEVINSKY 0, HONIGFELD G, PATIN J: Clozapine-related seizures. Neurology (1991) 41:369–371.
   PubMed Web of Science ®Google Scholar
• PACIA SV, DEVINSKY 0: Clozapine-related seizures: experience with 5,629 patients. Neurology (1994) 44:2247–2249.
   PubMed Web of Science ®Google Scholar
• HALLER E, BINDER RL: Clozapine andseizures. Am. J. Psychiatry (1990) 147:1069–1071.
   PubMed Web of Science ®Google Scholar
• ERESHEFSKY L: Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. j Clin. Psychiatry (1999) 60\(Suppl. 10):20–30.
   Google Scholar
• DEVINSKY 0, PACIA SV: Seizures during clozapine therapy. I OM. Psychiatry (1994) 55(Suppl. B):153–156.
   Google Scholar
• ••Reviews the clinical and radiologicalfeatures of seizures caused by clozapine as well as management of these seizures.
   Google Scholar
• NO AUTHORS LISTED: Physicians' Desk Reference. Medical Economics Company, Inc., Montvale (1999).
   Google Scholar
• LEE JW, CRISMON ML, DORSON PG: Seizure associated with olanzapine. Ann. Pharmacother. (1999) 33:554–556.
   PubMed Web of Science ®Google Scholar
• WOOLLEY J, SMITH S: Lowered seizure threshold on olanzapine. Br I Psychiatry (2001) 178:85–86.
   PubMed Web of Science ®Google Scholar
• PILLMANN F, SCHLOTE K, BROICH K, MARNEROS A: Electroencephalogram alterations during treatment with olanzapine. Psychopharmacology (Berl) (2000) 150:216–219.
   PubMed Web of Science ®Google Scholar
• CENTORRINO F, PRICE BH, TUTTLE M et al.: EEG abnormalities during treatment with typical and atypical antipsychotics. Am. I Psychiatry (2002) 159:109–115.
   PubMed Web of Science ®Google Scholar
• WYDERSKI RJ, STARRETT WG, ABOU-SAIF A: Fatal status epilepticus associated with olanzapine therapy. Ann. Pharmacother. (1999) 33:787–789.
   PubMed Web of Science ®Google Scholar
• DESHAUER D, ALBUQUERQUE J, ALDA M, GROF P: Seizures caused by possible interaction between olanzapine and clomipramine. I Clin. Psychopharmacol (2000) 20:283–284.
   Google Scholar
• HEDGES DW, JEPPSON KG: New-onset seizure associated with quetiapine and olanzapine. Ann. Pharmacother. (2002) 36:437–439.
   PubMed Web of Science ®Google Scholar
• STAHL SM: Antipsychotic polypharmacy,Part 1: Therapeutic option or dirty little secret? J Clin Psychiatry (1999) 60:425–426.
   PubMed Web of Science ®Google Scholar
• ACRI AA, HENRETIG FM: Effects of risperidone in overdose. Am. I Emerg. Med. (1998) 16:498–501.
   PubMed Web of Science ®Google Scholar
• LANE HY, CHANG WH, CHOU JC: Seizure during risperidone treatment in an elderly woman treated with concomitant medications. J Clin Psychiatry (1998) 59:81–82.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Drug InteractionFacts (2002).
   Google Scholar
• PERRY PJ, ALEXANDER B, LISKOW BI: Psychotropic Drug Handbook. American Psychiatric Press, Inc., Washington, DC (1997):1–740.
   Google Scholar
• JUNGHAN U, ALBERS M, WOGGON B: Increased risk of hematological side-effects in psychiatric patients treated with clozapine and carbamazepine? Pharmacopsychiatry (1993) 26:262.
   PubMed Web of Science ®Google Scholar
• CATALANO G, CATALANO MC, HANLEY PF: Seizures associated with buspirone overdose: case report and literature review. Clin Neuropharmacol (1998) 21:347–350.
   PubMed Web of Science ®Google Scholar
• LANGLOIS RP PAQUETTE D: Sustained bradycardia during fluvoxamine and buspirone intoxication. Can. I Psychiatry (1994) 39:126–127.
   PubMed Web of Science ®Google Scholar
• TILLER JW, BURROWS GD, O'SULLIVAN BT: Buspirone overdose. Med. J. Aust. (1989) 150:54.
   PubMedGoogle Scholar
• GRADY TA, PIGOTT TA, L'HEUREUX F, MURPHY DL: Seizure associated with fluoxetine and adjuvant buspirone therapy. Psychopharmacol (1992) 12:70–71.
   Web of Science ®Google Scholar
• SANOFI-SYNTHELABO: Ambien (Zolpidem tartrate). Prescribing Information (2002).
   Google Scholar
• GILBERT DL, STAATS PS: Seizure after withdrawal from supratherapeutic doses of zolpidem tartrate, a selective omega I benzodiazepine receptor agonist. I Pain Symptom Manage. (1997) 14:118–120.
   PubMed Web of Science ®Google Scholar
• ARAGONA M: Abuse, dependence, and epileptic seizures after zolpidem withdrawal: review and case report. Neuropharmacol (2000) 23:281–283.
   Web of Science ®Google Scholar
• CAVALLARO R, REGAZZETTI MG, COVELLI G, SMERALDI E: Tolerance and withdrawal with zolpidem. Lancet (1993) 342:374–375.
   PubMed Web of Science ®Google Scholar
• GERICKE CA, LUDOLPH AC: Chronic abuse of zolpidem. JAMA (1994) 272:1721–1722.
   PubMed Web of Science ®Google Scholar
• JULOU L, BARDONE MC, BLANCHARD JC, GARRET C, STUTZMANN JM: Pharmacological studies on zopiclone. Pharmacology (1983) 27\(Suppl. 2):46–58.
   Google Scholar
• ARANKO K, HENRIKSSON M, HUBLIN C, SEPPALAINEN AM: Misuse of zopiclone and convulsions during withdrawal. Pharmacopsychiatry (1991) 24:138–140.
   PubMed Web of Science ®Google Scholar
• SIMARD M, GUMBINER B, LEE A, LEWIS H, NORMAN D: Lithium carbonate intoxication. A case report and review of the literature. Arch. Intern. Med. (1989) 149:36–46.
   PubMed Web of Science ®Google Scholar
• ALLDREDGE BK, SIMON RP: Drugs that can precipitate seizures. The Medical Treatment of Epilepsy. New York (1992).
   Google Scholar
• EL-MALLAKH RS: Complications of concurrent lithium and electroconvulsive therapy: a review of clinical material and theoretical considerations. Biol. Psychiatry (1988) 23:586–594.
   PubMedGoogle Scholar
• JHA AK, STEIN GS, FEN WICK P: Negative interaction between lithium and electroconvulsive therapy - a case-control study. Br. J. Psychiatry (1996) 168:241–243.
   PubMed Web of Science ®Google Scholar
• PENNEY JF, DINWIDDIE SH, ZORUMSKI CF, WETZEL RD: Concurrent and close temporal administration of lithium and ECT. Con vuls. Ther. (1990) 4:40–45.
   Google Scholar
• COPPEN M, ABOU-SALEH MT, MILLN P et al: Lithium continuation therapy following electroconvulsive therapy. Br. J. Psychiatry (1981) 139:284–287.
   PubMed Web of Science ®Google Scholar
• ASSOCIATION AP: The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training and Privileging. American Psychiatric Press, Washington, DC (2001).
   Google Scholar
• CONWAY CR, NELSON LA: The combined use of bupropion, lithium, and venlafaxine during ECT: a case of prolonged seizure activity. I ECT (2001) 17:216–218.
   PubMed Web of Science ®Google Scholar
• JUS A, VILLENEUVE A, GAUTIER J et al.: Influence of lithium carbonate on patients with temporal epilepsy. Can. Psychiatr. Assoc. J. (1973) 18:77–78.
   PubMedGoogle Scholar
• SHUKLA S, MUKHERJEE S, DECINA P: Lithium in the treatment of bipolar disorders associated with epilepsy: an open study. Psychopharmacol (1988) 8:201–204.
   Web of Science ®Google Scholar
• ERWIN CW, GERBER CJ, MORRISON SD, JAMES JF: Lithium carbonate and convulsive disorders. Arch. Cm Psychiatry (1973) 28:646–648.
   PubMed Web of Science ®Google Scholar
• FINLEY PR, WARNER MD, PEABODY CA: Clinical relevance of drug interactions with lithium. Clin Pharmacy/dna. (1995) 29:172–191.
   Google Scholar
• HARVEY NS, MERRIMAN S: Review of clinically important drug interactions with lithium. Drug Sal (1994) 10:455–463.
   PubMed Web of Science ®Google Scholar
• GRANNEMAN GR, SCHNECK DW, CAVANAUGH JH, WITT GF: Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. j Clin. Psychiatry (1996) 57:204–206.
   PubMed Web of Science ®Google Scholar
• CHEN C, VERONESE L, YIN Y: The effects of lamotrigine on the pharmacokinetics of lithium. Br j Clin. Phannacol (2000) 50:193–195.
   PubMed Web of Science ®Google Scholar
• FRYE MA, KIMBRELL TA, DUNN RT et al.: Gabapentin does not alter single-dose lithium pharmacokinetics. j Clin. Psychophannacol (1998) 18:461–464.
   Web of Science ®Google Scholar
• PINNINTI NR, ZELINSKI G: Does topiramate elevate serum lithium levels? I Clin. Psychophannacol (2002) 22:340.
   Web of Science ®Google Scholar
• GARCIA G, CRISMON ML, DORSON PG: Seizures in two patients after the addition of lithium to a clozapine regimen. j Clin. Psychophannacol (1994) 14:426–428.
   Web of Science ®Google Scholar
• BLAKE LM, MARKS RC, LUCHINS DJ: Reversible neurologic symptoms with clozapine and lithium. j Clin. Psychophannacol (1992) 12:297–299.
   Web of Science ®Google Scholar
• BOWDEN CL: Lamotrigine in the treatment of bipolar disorder. Expert Opin. Phannacother. (2002) 3:1513–1519.
   PubMedGoogle Scholar
• KECK PE, MCELROY SL: Carbamazepine and valproate in the maintenance treatment of bipolar disorder. j Clin. Psychiatry (2002) 63\(Suppl. 10):13–17.
   Google Scholar
• SO EL, RUGGLES KH, CASCINO GD, AHMANN PA, WEATHERFORD KW: Seizure exacerbation and status epilepticus related to carbamazepine-10,11-epoxide. Ann. Neural (1994) 35:743–746.
   PubMed Web of Science ®Google Scholar
• WEAVER DF, CAMFIELD E FRASER A: Massive carbamazepine overdose: clinical and pharmacologic observations in five episodes. Neurology (1988) 38:755–759.
   PubMed Web of Science ®Google Scholar
• GUERRINI R, BELMONTE A, GENTON P: Antiepileptic drug-induced worsening of seizures. Epilepsia (1998) 39\(Suppl. 3):52–S10.
   Google Scholar
• •A comprehensive review that also includes a discussion of patient-related factors that increase the risk of exacerbation.
   Google Scholar
• BERKOVIC SF: Aggravation of generalized epilepsies. Epilepsia (1998) 39\(Suppl. 3):S11–S14.
   Google Scholar
• PISANI F, FAZIO A, ARTESI C et al: Elevation of plasma phenytoin by viloxazine in epileptic patients: a clinically significant drug interaction. I Neural Neurosurg. Psychiatry (1992) 55:126–127.
   PubMed Web of Science ®Google Scholar
• ROMERO AS, DELGADO RG, PENA MF: Interaction between trazodone and carbamazepine. Ann. Phanncother. (1999) 33:1370.
   PubMed Web of Science ®Google Scholar
• GRIMSLEY SR, JANN MW, CARTER JG, D'MELLO AP D'SOUZA MJ: Increased carbamazepine plasma concentrations after fluoxetine coadministration. Phannacol Ther. (1991) 50:10–15.
   PubMed Web of Science ®Google Scholar
• FRITZE J, UNSORG B, LANCZIK M: Interaction between carbamazepine and fluvoxamine. Acta Psychiatr. Land. (1991) 84:583–584.
   PubMed Web of Science ®Google Scholar
• SPINA E, PERUCCA E: Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia (2002) 43\(Suppl. 2):37–44.
   Google Scholar
• •The authors emphasise a mechanistic approach to drug interactions by identifying substrates, inhibitors and inducers of specific CYP450 isoforms. This entire supplement issue of Epilepsia is devoted to the use of psychotropic drugs in patients with epilepsy.
   Google Scholar
• STEINMAN GS, WOERPEL RW, SHERARD ES: Treatment of accidental sodium valproate overdose with an opiate antagonist. Ann. Neural (1979) 6:274.
   PubMed Web of Science ®Google Scholar
• EEG-OLOFSSON 0, LINDSKOG U: Acute intoxication with valproate. Lancet (1982) 8284:1306.
   Google Scholar
• DI MARIO FJ, CALANCY RR: Pardoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures. Pediati: Neural. (1988) 4:249–251.
   PubMed Web of Science ®Google Scholar
• BITTENCOURT PRIVI, RICHENS A: Anticonvulsant-induced status epilepticus in Lennox-Gastaut syndrome. Epilepsia (1991) 22:129–134.
   Google Scholar
• KONIG SA, SIEMES H, BLAKER F et al: Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia (1994) 35:1005–1015.
   PubMed Web of Science ®Google Scholar
• JANSZKY J, RASONYI G, HALASZ P et al.: Disabling erratic myoclonus during lamotrigine therapy with high serum level: report of two cases. Clin. Neurophannacol (2000) 23:86–89.
   PubMed Web of Science ®Google Scholar
• GUERRINI R, BELMONTE A, PARMEGGIANI L, PERUCCA E: Myoclonic status epilepticus following high-dosage lamotrigine therapy. Brain Dev. (1999) 21:420–424.
   PubMed Web of Science ®Google Scholar
• ALLDREDGE BK, LOWENSTEIN DH: Status epilepticus related to alcohol abuse. Epilepsia (1993) 34:1033–1037.
   PubMed Web of Science ®Google Scholar
• ALLDREDGE BK, LOWENSTEIN DH, SIMON RP: Seizures associated with recreational drug abuse. Neurology (1989) 39:1037–1039.
   PubMed Web of Science ®Google Scholar
• DAWKINS K, EKSTROM RD, HILL MA, ISAACS DL, GOLDEN RN: Ethnicity and seizure threshold. Prog. Neuropsychophannacol Biol. Psychiatry (2000) 24:1289–1298.
   PubMed Web of Science ®Google Scholar
• MARKS RC, LUCHINS DJ: Antipsychotic medications and seizures. Psychiatr. Med. (1991) 9:37-52. Affiliation
   Google Scholar